Novel therapies to achieve the recommended low-density lipoprotein cholesterol concentration (LDL-C) targets for patients after coronary artery bypass grafting

Salil V Deo; Sadeer Al-Kindi; Salim S Virani; Stephen Fremes

doi:10.1016/j.jtcvs.2023.05.028

Novel therapies to achieve the recommended low-density lipoprotein cholesterol concentration (LDL-C) targets for patients after coronary artery bypass grafting

J Thorac Cardiovasc Surg. 2024 Feb;167(2):723-730.e4. doi: 10.1016/j.jtcvs.2023.05.028. Epub 2023 Jun 5.

Authors

Salil V Deo¹, Sadeer Al-Kindi², Salim S Virani³, Stephen Fremes⁴

Affiliations

¹ Surgical Services, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio; School of Medicine, Case Western Reserve University, Cleveland, Ohio; School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom. Electronic address: svd14@case.edu.
² School of Medicine, Case Western Reserve University, Cleveland, Ohio; Harrington Heart and Vascular Institute, University Hospitals, Cleveland, Ohio.
³ The Aga Khan University, Karachi, Pakistan; Texas Heart Institute and Baylor College of Medicine, Houston, Tex.
⁴ Division of Cardiac Surgery, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

PMID: 37286075
DOI: 10.1016/j.jtcvs.2023.05.028

No abstract available

Keywords: PSCK9 inhibitor; atherosclerosis; bempedoic acid; coronary artery bypass grafting; coronary artery disease; ezetimibe; inclisiran; statin intolerance; statin-associated muscle symptoms.

Publication types

Editorial
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Anticholesteremic Agents*
Cholesterol, LDL
Coronary Artery Bypass / adverse effects
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Hypercholesterolemia*

Substances

Cholesterol, LDL
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors